Literature DB >> 31838832

Middle East Respiratory Syndrome-Coronavirus Infection into Established hDPP4-Transgenic Mice Accelerates Lung Damage Via Activation of the Pro-Inflammatory Response and Pulmonary Fibrosis.

Ju Kim1, Ye Lin Yang2, Yongsu Jeong3, Yong-Suk Jang1,2.   

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) infects the lower respiratory airway of humans, leading to severe acute respiratory failure. Unlike human dipeptidyl peptidase 4 (hDPP4), a receptor for MERS-CoV, mouse DPP4 (mDPP4) failed to support MERS-CoV infection. Consequently, diverse transgenic mouse models expressing hDPP4 have been developed using diverse methods, although some models show no mortality and/or only transient and mild-to-moderate clinical signs following MERS-CoV infection. Additionally, overexpressed hDPP4 is associated with neurological complications and breeding difficulties in some transgenic mice, resulting in impeding further studies. Here, we generated stable hDPP4-transgenic mice that were sufficiently susceptible to MERS-CoV infection. The transgenic mice showed weight loss, decreased pulmonary function, and increased mortality with minimal perturbation of overexpressed hDPP4 after MERS-CoV infection. In addition, we observed histopathological signs indicative of progressive pulmonary fibrosis, including thickened alveolar septa, infiltration of inflammatory monocytes, and macrophage polarization as well as elevated expression of profibrotic molecules and acute inflammatory response in the lung of MERS-CoV-infected hDPP4-transgenic mice. Collectively, we suggest that this hDPP4-transgenic mouse is useful in understanding the pathogenesis of MERS-CoV infection and for antiviral research and vaccine development against the virus.

Entities:  

Keywords:  Aanimal model; MERS-CoV; hDPP4; pathogenesis; transgenic mouse

Mesh:

Substances:

Year:  2020        PMID: 31838832     DOI: 10.4014/jmb.1910.10055

Source DB:  PubMed          Journal:  J Microbiol Biotechnol        ISSN: 1017-7825            Impact factor:   2.351


  14 in total

Review 1.  Mesenchymal stem cell alongside exosomes as a novel cell-based therapy for COVID-19: A review study.

Authors:  Meruyert Dauletova; Hafsan Hafsan; Negah Mahhengam; Angelina Olegovna Zekiy; Majid Ahmadi; Homayoon Siahmansouri
Journal:  Clin Immunol       Date:  2021-03-06       Impact factor: 10.190

2.  Conjugation of Human β-Defensin 2 to Spike Protein Receptor-Binding Domain Induces Antigen-Specific Protective Immunity against Middle East Respiratory Syndrome Coronavirus Infection in Human Dipeptidyl Peptidase 4 Transgenic Mice.

Authors:  Ju Kim; Ye Lin Yang; Yongsu Jeong; Yong-Suk Jang
Journal:  Vaccines (Basel)       Date:  2020-11-01

Review 3.  Peptides-based therapeutics: Emerging potential therapeutic agents for COVID-19.

Authors:  Jagat Narayan Shah; Guang-Qin Guo; Anand Krishnan; Muthusamy Ramesh; Naresh Kumar Katari; Mohd Shahbaaz; Magda H Abdellattif; Sachin Kumar Singh; Kamal Dua
Journal:  Therapie       Date:  2021-10-08       Impact factor: 3.367

Review 4.  Clinical Symptoms and Types of Samples Are Critical Factors for the Molecular Diagnosis of Symptomatic COVID-19 Patients: A Systematic Literature Review.

Authors:  Milad Zandi; Abbas Farahani; Armin Zakeri; Sara Akhavan Rezayat; Ramin Mohammadi; Umashankar Das; Jonathan R Dimmock; Shervin Afzali; Mohammadvala Ashtar Nakhaei; Alireza Doroudi; Yousef Erfani; Saber Soltani
Journal:  Int J Microbiol       Date:  2021-09-06

5.  Increased Expression of Tim-3 Is Associated With Depletion of NKT Cells In SARS-CoV-2 Infection.

Authors:  Jingzhi Yang; Teding Chang; Liangsheng Tang; Hai Deng; Deng Chen; Jialiu Luo; Han Wu; TingXuan Tang; Cong Zhang; Zhenwen Li; Liming Dong; Xiang-Ping Yang; Zhao-Hui Tang
Journal:  Front Immunol       Date:  2022-02-16       Impact factor: 7.561

6.  Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors.

Authors:  Urszula Radzikowska; Mei Ding; Ge Tan; Damir Zhakparov; Yaqi Peng; Paulina Wawrzyniak; Ming Wang; Shuo Li; Hideaki Morita; Can Altunbulakli; Matthias Reiger; Avidan U Neumann; Nonhlanhla Lunjani; Claudia Traidl-Hoffmann; Kari C Nadeau; Liam O'Mahony; Cezmi Akdis; Milena Sokolowska
Journal:  Allergy       Date:  2020-08-24       Impact factor: 14.710

Review 7.  T Cells in Fibrosis and Fibrotic Diseases.

Authors:  Mengjuan Zhang; Song Zhang
Journal:  Front Immunol       Date:  2020-06-26       Impact factor: 7.561

Review 8.  Mesenchymal Stem Cell Derived Exosomes: a Nano Platform for Therapeutics and Drug Delivery in Combating COVID-19.

Authors:  Suchi Gupta; Vishnu Krishnakumar; Yashvi Sharma; Amit Kumar Dinda; Sujata Mohanty
Journal:  Stem Cell Rev Rep       Date:  2021-02       Impact factor: 6.692

9.  SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?

Authors:  Dario Pitocco; Linda Tartaglione; Luca Viti; Mauro Di Leo; Alfredo Pontecorvi; Salvatore Caputo
Journal:  Diabetes Res Clin Pract       Date:  2020-04-23       Impact factor: 5.602

Review 10.  COVID-19 vaccines: The status and perspectives in delivery points of view.

Authors:  Jee Young Chung; Melissa N Thone; Young Jik Kwon
Journal:  Adv Drug Deliv Rev       Date:  2020-12-24       Impact factor: 17.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.